Archives of Advances in Biosciences

Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018; 8(2):317-31. [PMID] [PMCID]

Zhang Y, Luo M, Xu W, Yang M, Wang B, Gao J, et al. Avermectin confers its cytotoxic effects by inducing DNA damage and mitochondria-associated apoptosis. J Agric Food Chem. 2016; 64(36):6895-902. [DOI:10.1021/acs.jafc.6b02812] [PMID]

Albérich M, Ménez C, Sutra JF, Lespine A. Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in mice. Eur J Pharmacol. 2014; 740:428-35. [DOI:10.1016/j.ejphar.2014.06.052] [PMID]

Zhang Y, Wu J, Xu W, Gao J, Cao H, Yang M, et al. Cytotoxic effects of avermectin on human HepG2 cells in vitro bioassays. Environ Pollut. 2017; 220(Pt B):1127-37. [DOI:10.1016/j.envpol.2016.11.022] [PMID]

Crump A. Ivermectin: Enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot. 2017; 70(5):495-505. [DOI:10.1038/ja.2017.11] [PMID]

Gloeckner Ch, Garner AL, Mersha F, Oksov Y, Tricoche N, Eubanks LM, et al. Repositioning of an existing drug for the neglected tropical disease onchocerciasis. Proc Natl Acad Sci U S A. 2010; 107(8):3424-9. [DOI:10.1073/pnas.0915125107] [PMID] [PMCID]

Hosseini Bai Sh, Ogbourne S. Eco-toxicological effects of the avermectin family with a focus on abamectin and ivermectin. Chemosphere. 2016; 154:204-14. [DOI:10.1016/j.chemosphere.2016.03.113] [PMID]

Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: An overview of safety for an increasing number of indications. J Drugs Dermatol. 2016; 15(3):325-32. [PMID]

Canga AG, Prieto AMS, Liébana MJD, Martínez NF, Vega MS, Vieitez JJG. The pharmacokinetics and interactions of ivermectin in humans — A mini-review. AAPS J. 2008; 10(1):42-6. [DOI:10.1208/s12248-007-9000-9] [PMID] [PMCID]

Kaur H, Shekhar N, Sharma S, Sarma Ph, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol Rep. 2021; 73(3):736-49. [DOI:10.1007/s43440-020-00195-y] [PMID] [PMCID]

Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother. 1994; 34(2):195-203. [DOI:10.1093/jac/34.2.195] [PMID]

Crump A, Omura S. Ivermectin, ‘wonder drug’ from Japan: The human use perspective. Proc Jpn Acad Ser B. 2011; 87(2):13-28. [DOI:10.2183/pjab.87.13] [PMID] [PMCID]

van Wyk JA, Malan FS, Randles JL. How long before resistance makes it impossible to control some field strains of Haemonchus contortus in South Africa with any of the modern anthelmintics? Vet Parasitol. 1997; 70(1-3):111-22. [DOI:10.1016/S0304-4017(96)01147-8]

McKellar QA, Benchaoui HA. Avermectins and milbemycins. J Vet Pharmacol Ther. 1996; 19(5):331-51. [DOI:10.1111/j.1365-2885.1996.tb00062.x] [PMID]

Burkhart CN. Ivermectin: An assessment of its pharmacology, microbiology and safety. Vet Hum Toxicol. 2000; 42(1):30-5. [PMID]

Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, et al. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol. 1997; 146(1):88-94. [DOI:10.1006/taap.1997.8225] [PMID]

Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: Pharmacology and application in dermatology. Int J Dermatol. 2005; 44(12):981-8. [DOI:10.1111/j.1365-4632.2004.02253.x] [PMID]

De Sole G, Awadzi K, Remme J, Dadzie KY, Ba O, Giese J, et al. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactions. Trop Med Parasitol. 1989; 40(3):375-82. [PMID]

Ashour DS. Ivermectin: From theory to clinical application. Int J Antimicrob Agents. 2019; 54(2):134-42. [DOI:10.1016/j.ijantimicag.2019.05.003] [PMID]

El-Azzouni MZ. Effect of ivermectin on experimental trichinosis. J Egypt Soc Parasitol. 1997; 27(2):331-40. [PMID]

Ōmura S, Crump A. Ivermectin and malaria control. Malar J. 2017; 16:172. [DOI:10.1186/s12936-017-1825-9] [PMID] [PMCID]

Osorio J, Moncada L, Molano A, Valderrama S, Gualtero S, Franco-Paredes C. Role of ivermectin in the treatment of severe orbital myiasis due to Cochliomyia hominivorax. Clin Infect Dis. 2006; 43(6):e57-9. [DOI:10.1086/507038] [PMID]

Kadir MA, Aswad HS, Al-Samarai AM, Al-Mula GA. Comparison between the efficacy of ivermectin and other drugs in treatment of cutaneous leishmaniasis. Iraqi J Vet Sci. 2009; 23(Suppl II):175-80. https://www.researchgate.net/publication/237481636

Alsharif A, Sodhi A, Murillo LC, Headley AS, Kadaria D. Wait!!! no steroids for this asthma…. Am J Case Rep. 2015; 16:398-400. [DOI:10.12659/AJCR.893729] [PMID] [PMCID]

Colebunders R, Mandro M, Mukendi D, Dolo H, Suykerbuyk P, Van Oijen M. Ivermectin treatment in patients with onchocerciasis-associated epilepsy: Protocol of a randomized clinical trial. JMIR Res Protoc. 2017; 6(8):e137. [DOI:10.2196/resprot.7186] [PMID] [PMCID]

Udensi UK, Fagbenro-Beyioku AF. Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice. J Vector Borne Dis. 2012; 49(3):143-50. [PMID]

Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot. 2020; 73(9):593-602. [DOI:10.1038/s41429-020-0336-z] [PMID] [PMCID]

Yang SNY, Atkinson SC, Wang Ch, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020; 177:104760. [DOI:10.1016/j.antiviral.2020.104760] [PMID]

Csóka B, Németh ZH, Szabó I, Davies DL, Varga ZV, Pálóczi J, et al. Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI Insight. 2018; 3(11):e99431. [DOI:10.1172/jci.insight.99431] [PMID] [PMCID]

Kane NS, Hirschberg B, Qian S, Hunt D, Thomas B, Brochu R, et al. Drug-resistant Drosophila indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and ivermectin. Proc Natl Acad Sci U S A. 2000; 97(25):13949-54. [DOI:10.1073/pnas.240464697] [PMID] [PMCID]

Njoo FL, Hack CE, Oosting J, Luyendijk L, Stilma JS, Kijlstra A. C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment. J Infect Dis. 1994; 170(3):663-8. [DOI:10.1093/infdis/170.3.663] [PMID]

Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: Trends, scope and relevance. New Microbes New Infect. 2020; 35:100684. [DOI:10.1016/j.nmni.2020.100684] [PMID] [PMCID]

Scheim D. Ivermectin for COVID-19 treatment: Clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion [Internet]. 2020 [Updated 2021 August 22]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3636557 [DOI:10.2139/ssrn.3636557]

Rizzo E. Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. 2020; 393(7):1153-6. [DOI:10.1007/s00210-020-01902-5] [PMID] [PMCID]

Priel A, Silberberg SD. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004; 123(3):281-93. [DOI:10.1085/jgp.200308986] [PMID] [PMCID]

Stokes L, Layhadi JA, Bibic L, Dhuna K, Fountain SJ. P2X4 receptor function in the nervous system and current breakthroughs in pharmacology. Front Pharmacol. 2017; 8:291. [DOI:10.3389/fphar.2017.00291] [PMID] [PMCID]

Shinohara EH, Martini MZ, de Oliveira Neto HG, Takahashi A. Oral myiasis treated with ivermectin: Case report. Braz Dent J. 2004; 15(1):79-81. [DOI:10.1590/S0103-64402004000100015] [PMID]

Pandey TR, Shrestha GB, Sitaula RK, Shah DN. A case of orbital myiasis in recurrent eyelid basal cell carcinoma invasive into the orbit. Case Rep Ophthalmol Med. 2016; 2016:2904346. [DOI:10.1155/2016/2904346] [PMID] [PMCID]

Basyoni MMA, El-Sabaa AAA. Therapeutic potential of myrrh and ivermectin against experimental Trichinella spiralis infection in mice. Korean J Parasitol. 2013; 51(3):297-304. [DOI:10.3347/kjp.2013.51.3.297] [PMID] [PMCID]

Tesh RB, Guzman H. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am J Trop Med Hyg. 1990; 43(3):229-33. [DOI:10.4269/ajtmh.1990.43.229] [PMID]

Chaccour C, Lines J, Whitty CJM. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: The potential of oral insecticides in malaria control. J Infect Dis. 2010; 202(1):113-6. [DOI:10.1086/653208] [PMID]

Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010; 116(2):119-26. [DOI:10.1016/j.actatropica.2010.06.001] [PMID] [PMCID]

Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011; 85(1):3-5. [DOI:10.4269/ajtmh.2011.11-0160] [PMID] [PMCID]

Panchal M, Rawat K, Kumar G, Kibria KM, Singh S, Kalamuddin M, et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 2014; 5:e994. [DOI:10.1038/cddis.2013.521] [PMID] [PMCID]

Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M. Endectocides for malaria control. Trends Parasitol. 2011; 27(10):423-8. [DOI:10.1016/j.pt.2011.05.007] [PMID] [PMCID]

Mascari TM, Mitchell MA, Rowton ED, Foil LD. Ivermectin as a rodent feed-through insecticide for control of immature sand flies (Diptera: Psychodidae). J Am Mosq Control Assoc. 2008; 24(2):323-6. [DOI:10.2987/5678.1] [PMID]

Hanafi HA, Szumlas DE, Fryauff DJ, El-Hossary SS, Singer GA, Osman SG, et al. Effects of ivermectin on blood-feeding Phlebotomus papatasi, and the promastigote stage of Leishmania major. Vector Borne Zoonotic Dis. 2011; 11(1):43-52. [DOI:10.1089/vbz.2009.0030] [PMID]

Rasheid KA, Morsy TA. Efficacy of ivermectin on the infectivity of Leishmania major promastigotes. J Egypt Soc Parasitol. 1998; 28(1):207-12. [PMID]

Opara WEK, Ameh IG. Cutaneous leishmaniasis: a report of its treatment with Mectizan in Sokoto, Nigeria. J Med Sci. 2005; 5(3):186-8. [DOI:10.3923/jms.2005.186.188]

Distelmans W, D’Haeseleer F, Mortelmans J. Efficacy of systemic administration of ivermectin against tsetse flies. Ann Soc Belg Med Trop. 1983; 63(2):119-25. [PMID]

Pooda SH, Mouline K, De Meeûs T, Bengaly Z, Solano Ph. Decrease in survival and fecundity of Glossina palpalis gambiensis vanderplank 1949 (Diptera: Glossinidae) fed on cattle treated with single doses of ivermectin. Parasit Vectors. 2013; 6:165. [DOI:10.1186/1756-3305-6-165] [PMID] [PMCID]

Dias JCP, Schofield CJ, Machado EM, Fernandes AJ. Ticks, ivermectin, and experimental Chagas disease. Mem Inst Oswaldo Cruz. 2005; 100(8):829-32. [DOI:10.1590/S0074-02762005000800002] [PMID]

Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: Resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg. 1994; 51(1):83-8. [DOI:10.4269/ajtmh.1994.51.83] [PMID]

Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, et al. Resistance to praziquantel: Direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999; 60(6):932-5. [DOI:10.4269/ajtmh.1999.60.932] [PMID]

Mendonça-Silva DL, Pessôa RF, Noël F. Evidence for the presence of glutamatergic receptors in adult Schistosoma mansoni. Biochem Pharmacol. 2002; 64(9):1337-44. [DOI:10.1016/S0006-2952(02)01358-8]

Lynagh T, Lynch JW. Ivermectin binding sites in human and invertebrate Cys-loop receptors. Trends Pharmacol Sci. 2012; 33(8):432-41. [DOI:10.1016/j.tips.2012.05.002] [PMID]

Taman A, Ribeiro P. Characterization of a truncated metabotropic glutamate receptor in a primitive metazoan, the parasitic flatworm Schistosoma mansoni. PLoS One. 2011; 6(11):e27119. [DOI:10.1371/journal.pone.0027119] [PMID] [PMCID]

Taman A, El-Beshbishi S, El-Tantawy N, El-Hawary A, Azab M. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. J Coast Life Med. 2014; 2(10):817-23. https://www.researchgate.net/publication/263466782

Alves SN, de Melo AL. Effects of benzodiazepine and ivermectin on Girardiatigrina (Platyhelminthes: Turbellaria). Biosci J. 2013; 29(1):209-15. https://seer.ufu.br/index.php/biosciencejournal/article/view/14413

Maťha V, Weiser J. Molluscicidal effect of ivermectin on Biomphalaria glabrata. J Invertebr Pathol. 1988; 52(2):354-5. [DOI:10.1016/0022-2011(88)90146-2]

Sheele JM, Anderson JF, Tran TD, Teng YA, Byers PA, Ravi BS, et al. Ivermectin causes Cimex lectularius (bedbug) morbidity and mortality. J Emerg Med. 2013; 45(3):433-40. [DOI:10.1016/j.jemermed.2013.05.014] [PMID]

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. [DOI:10.1016/j.antiviral.2020.104787] [PMID] [PMCID]

Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021; 103:214-6. [DOI:10.1016/j.ijid.2020.11.191] [PMID] [PMCID]

Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents. 2021; 57(1):106248. [DOI:10.1016/j.ijantimicag.2020.106248] [PMID] [PMCID]

de Castro Jr CG, Gregianin LJ, Burger JA. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma. 2020; 61(10):2536-7. [DOI:10.1080/10428194.2020.1786559] [PMID]

Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021; 7(7):CD015017. [DOI:10.1002/14651858.CD015017] [PMID] [PMCID]

Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 2016; 20(2):259-70. [DOI:10.1016/j.chom.2016.07.004] [PMID] [PMCID]

Ketkar H, Yang L, Wormser GP, Wang P. Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diagn Microbiol Infect Dis. 2019; 95(1):38-40. [DOI:10.1016/j.diagmicrobio.2019.03.012] [PMID] [PMCID]

Ji W, Luo G. Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication. Virology. 2020; 541:124-35. [DOI:10.1016/j.virol.2019.10.010] [PMID]

Tay MYF, Fraser JE, Chan WKK, Moreland NJ, Rathore AP, Wang C, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; Protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013; 99(3):301-6. [DOI:10.1016/j.antiviral.2013.06.002] [PMID]

Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012; 443(3):851-6. [DOI:10.1042/BJ20120150] [PMID] [PMCID]

Surnar B, Kamran MZ, Shah AS, Basu U, Kolishetti N, Deo S, et al. Orally administrable therapeutic synthetic nanoparticle for Zika virus. ACS Nano. 2019; 13(10):11034-48. [DOI:10.1021/acsnano.9b02807] [PMID] [PMCID]

Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug. J Antimicrob Chemother. 2012; 67(8):1884-94. [DOI:10.1093/jac/dks147] [PMID] [PMCID]

Götz V, Magar L, Dornfeld D, Giese S, Pohlmann A, Höper D, et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Scientific reports, 2016; 6(1): 1-15. [DOI: http://dx.doi.org/10.1038/srep23138]

Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011; 16(2):192-200. [DOI:10.1177/1087057110390360] [PMID]

Azeem S, Ashraf M, Rasheed MA, Anjum AA, Hameed R. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak J Pharm Sci. 2015; 28(2):597-602. [PMID]

Ashraf Sh, Chaudhry U, Raza A, Ghosh D, Zhao X. In vitro activity of ivermectin against Staphylococcus aureus clinical isolates. Antimicrob Resist Infect Control. 2018; 7:27. [DOI:10.1186/s13756-018-0314-4] [PMID] [PMCID]

Tan X, Xie H, Zhang B, Zhou J, Dou Zh, Wang X, et al. A novel ivermectin-derived compound D4 and its antimicrobial/biofilm properties against MRSA. Antibiotics. 2021; 10(2):208. [DOI:10.3390/antibiotics10020208] [PMID] [PMCID]

Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008; 4(2):68-75. [DOI:10.4161/org.4.2.5851] [PMID] [PMCID]

Wang Y, Wang Sh, Lei M, Boyett M, Tsui H, Liu W, et al. The p21-activated kinase 1 (Pak1) signalling pathway in cardiac disease: From mechanistic study to therapeutic exploration. Br J Pharmacol. 2018; 175(8):1362-74. [DOI:10.1111/bph.13872] [PMID] [PMCID]

Allegra A, Pioggia G, Innao V, Musolino C, Gangemi S. New insights into YES-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges. Cancers. 2021; 13(8):1981. [DOI:10.3390/cancers13081981] [PMID] [PMCID]

Dou Q, Chen HN, Wang K, Yuan K, Lei Y, Li K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 2016; 76(15):4457-69. [DOI:10.1158/0008-5472.CAN-15-2887] [PMID]

Diao H, Cheng N, Zhao Y, Xu H, Dong H, Thamm DH, et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Vet Res. 2019; 15:276. [DOI:10.1186/s12917-019-2026-2] [PMID] [PMCID]

Nambara Sh, Masuda T, Nishio M, Kuramitsu Sh, Tobo T, Ogawa Y, et al. Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget. 2017; 8(64):107666-77. [DOI:10.18632/oncotarget.22587] [PMID] [PMCID]

Melotti A, Mas Ch, Kuciak M, Lorente-Trigos A, Borges I, Ruiz i Altaba A. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014; 6(10):1263-78. [DOI:10.15252/emmm.201404084] [PMID] [PMCID]

Nishio M, Sugimachi K, Goto H, Wang J, Morikawa T, Miyachi Y, et al. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A. 2016; 113(1):E71-80. [DOI:10.1073/pnas.1517188113] [PMID] [PMCID]

Zhu M, Li Y, Zhou Zh. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage. Biochem Biophys Res Commun. 2017; 492(3):373-8. [DOI:10.1016/j.bbrc.2017.08.097] [PMID]

Nappi L, Aguda AH, Al Nakouzi N, Lelj-Garolla B, Beraldi E, Lallous N, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. 2020; 130(2):699-714. [DOI:10.1172/JCI130819] [PMID] [PMCID]

Sharmeen S, Skrtic M, Sukhai MA, Hurren R, Gronda M, Wang X, et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 2010; 116(18):3593-603. [DOI:10.1182/blood-2010-01-262675] [PMID]

Zhang P, Zhang Y, Liu K, Liu B, Xu W, Gao J, et al. Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway. Cell Prolif. 2019; 52(2):e12543. [DOI:10.1111/cpr.12543] [PMID] [PMCID]

Gallardo F, Teiti I, Rochaix Ph, Demilly E, Jullien D, Mariamé B, et al. Macrocyclic lactones block melanoma growth, metastases development and potentiate activity of anti-BRAF V600 inhibitors. Clin Skin Cancer. 2016; 1(1):4-14.e3. [DOI:10.1016/j.clsc.2016.05.001]